| Autor: |
Feighner, John P., Sverdlov, Lev, Nicolau, Gabriela, Abajian, Henry B., Hlavka, Joseph, Freed, Jeffrey S., Tonelli, George |
| Zdroj: |
The International Journal of Neuropsychopharmacology; September 2003, Vol. 6 Issue: 3 p207-207, 1p |
| Abstrakt: |
Data from two Phase 2 clinical studies with nemifitide, a novel pentapeptide antidepressant, were evaluated. The initial double-blind, placebo-controlled study was performed on outpatients with DSM-IV criteria for major depressive disorder. An open-label extension study enrolled subjects either completing or having been discontinued due to lack of efficacy during the follow-up period of the initial study. In the extension study, both the investigator and the subjects were blinded to the previous treatment in the initial study. No clinically significant side-effects were observed in either study. Twenty-seven subjects have been entered and evaluated in the extension study. Eighteen of these 27 subjects (66.7%) responded to re-treatment in the extension study. Mean duration of effect between re-treatments was 3.3 months. The results of the extension study support investigating a range of doses of nemifitide from 18 to 72 mg/d in future clinical trials. Further studies are planned to determine the most effective nemifitide clinical treatment regimen. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
